Johnson & Johnson (JNJ)
Summary
JNJ Chart
TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA® in Crohn's disease SAN DIEGO , May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC). The ASTRO Week 24 data build on the Week 12 SC induction data that showed statistically significant and clinically meaningful improvements compared to placebo across all clinical and endoscopic measures consistent with the U.S. Food and Drug Administration (FDA)-approved intravenous (IV) induction regimen evaluated in this population, in the Phase 3 QUASAR study.1,2 TREMFYA® is the first and only IL-23 inhibitor to demonstrate robust results with a fully SC regimen.
2 Bulletproof Dividend Stocks to Buy in May
Dividend stock investing has long been a cornerstone for building wealth, offering investors a steady stream of passive income while providing a buffer against market volatility.
J&J-backed HistoSonics explores sale at $2.5 billion valuation, FT reports
HistoSonics, a medical technology company backed by Johnson & Johnson , is exploring a potential sale after receiving multiple takeover approaches, the Financial Times reported on Friday, citing people familiar with the matter.
Johnson & Johnson Dividends
| JNJ 2 months ago | Other | €1.1 Per Share |
| JNJ 5 months ago | Other | €1.1 Per Share |
| JNJ 8 months ago | Other | €1.1 Per Share |
| JNJ 11 months ago | Other | €1.1 Per Share |
| JNJ 16 Feb 2024 | Other | €1.05 Per Share |
Johnson & Johnson Earnings
| 15 Apr 2025 Date | | - Cons. EPS | - EPS |
| 14 Apr 2025 Date | | - Cons. EPS | - EPS |
| 21 Jan 2025 Date | | - Cons. EPS | - EPS |
| 15 Oct 2024 Date | | - Cons. EPS | - EPS |
| 17 Jul 2024 Date | | - Cons. EPS | - EPS |
| JNJ 2 months ago | Other | €1.1 Per Share |
| JNJ 5 months ago | Other | €1.1 Per Share |
| JNJ 8 months ago | Other | €1.1 Per Share |
| JNJ 11 months ago | Other | €1.1 Per Share |
| JNJ 16 Feb 2024 | Other | €1.05 Per Share |
| 15 Apr 2025 Date | | - Cons. EPS | - EPS |
| 14 Apr 2025 Date | | - Cons. EPS | - EPS |
| 21 Jan 2025 Date | | - Cons. EPS | - EPS |
| 15 Oct 2024 Date | | - Cons. EPS | - EPS |
| 17 Jul 2024 Date | | - Cons. EPS | - EPS |
Johnson & Johnson (JNJ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Johnson & Johnson ever had a stock split?
Johnson & Johnson Profile
| Engineering & Construction Industry | Industrials Sector | Mr. Roberto Cecatto CEO | XMUN Exchange | US4781601046 ISIN |
| Italy Country | 600 Employees | 18 Feb 2025 Last Dividend | 13 Jun 2001 Last Split | - IPO Date |
Overview
Johnson & Johnson, a renowned entity in the healthcare sector, operates globally with a broad focus on research, development, manufacturing, and sales of healthcare products. The company is structured in multiple segments, primarily Innovative Medicine and MedTech, catering to a vast array of therapeutic areas and medical needs. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, illustrating a longstanding presence and commitment to healthcare innovation and advancement. Through its extensive product line and diversified service offerings, Johnson & Johnson reaches a wide audience, including retailers, wholesalers, distributors, hospitals, and healthcare professionals, providing prescription and non-prescription products alike.
Products and Services
The company's portfolio is divided into two main segments, each encompassing a variety of products and services designed to meet the complex demands of modern healthcare:
- Innovative Medicine:
This segment includes a range of products for different therapeutic areas. These encompass immunology (covering diseases like rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis), infectious diseases (including HIV/AIDS treatment), neuroscience (targeting mood disorders, neurodegenerative disorders, schizophrenia), oncology (focused on cancers such as prostate, lung, bladder, and hematologic malignancies), cardiovascular and metabolism (addressing conditions like thrombosis, diabetes, and macular degeneration), and pulmonary hypertension, specifically pulmonary arterial hypertension.
- MedTech:
This segment offers products and technologies across a range of medical fields. Interventional Solutions include electrophysiology products for heart rhythm disorders and technologies for severe coronary artery disease treatment. The neurovascular care line focuses on treating hemorrhagic and ischemic strokes. Orthopaedics products support treatments for hips, knees, trauma, spine, and sports injuries. The surgery portfolio covers advanced and general surgery technologies and solutions for breast aesthetics and ear, nose, and throat procedures. Additionally, MedTech offers visual health products like ACUVUE Brand contact lenses and TECNIS intraocular lenses for cataract surgery.
Contact Information
